According to the American Addiction Centers, benzodiazepine withdrawal symptoms typically start within 24 hours of treatment and can last from a few days to several months, depending on the length of abuse and strength of the benzodiazepine(s) used. The occurrence of withdrawal is dependent on the agent’s half-life and the amount of time it takes for the drug to leave the bloodstream. For shorter-acting benzodiazepines (e.g., alprazolam), withdrawal may start within 10 to 12 hours of stopping the medication, whereas with longer-acting benzodiazepines (e.g., diazepam), it may take a few days for symptoms to appear. In general, the early withdrawal phase usually starts within a few hours to a few days of stopping the medication and may last several days. Around 2 weeks after stopping a benzodiazepine, acute withdrawal may begin, which constitutes the bulk of withdrawal symptoms. Risk factors for increased benzodiazepine withdrawal duration and intensity include the length of time taking benzodiazepines, the dose of benzodiazepines taken, other medications being taken or abused, the method of administering benzodiazepines, and underlying mental health issues. [1]
A 2008 review discussing the risk of withdrawal upon discontinuation of benzodiazepines stated certain risk factors that may predict the occurrence or increased risk of withdrawal severity, such as higher benzodiazepine dose, longer duration of benzodiazepine use, and immediate cessation or rapid tapering of the benzodiazepine dose. Data reporting benzodiazepine withdrawal remain conflicting. Some studies suggest that benzodiazepine half-life does not influence withdrawal symptoms, whereas others indicate benzodiazepines with a short half-life are associated with a faster onset of withdrawal symptoms or more severe withdrawal symptoms when therapy is stopped abruptly compared with long half-life benzodiazepines. A specific incidence of withdrawal seizures or delirium tremens associated with specific benzodiazepines was not reported within the review. [2]
Another review from 2004 suggests that the risk of withdrawal symptoms and especially seizures is greater with benzodiazepines with short and intermediate half-lives. With the gradual taper, however, withdrawal seizures are rare and generally occur in patients taking a high dose for longer than 4 months. Patients with a history of seizures are also more likely to be at risk for seizures. Concomitant use of drugs that may lower the seizure threshold can further present a risk. In general, short- and intermediate-half-life compounds carry greater risks for a rebound, withdrawal reactions, and dependence than long-acting agents. Clonazepam and diazepam, benzodiazepines with longer half-lives, have been found to result in fewer rebound and withdrawal symptoms compared to alprazolam. [3]
A 1994 review describing the characterization of benzodiazepine withdrawal syndrome also states that short-lived rebound symptoms (e.g., anxiety, insomnia) onset within 1-4 days of discontinuation, depending on the half-life of the benzodiazepine. The second part of benzodiazepine withdrawal, the full-blown withdrawal syndrome, lasts about 10-14 days. A third part of the withdrawal is a return of anxiety symptoms, which persist until it is treated. Withdrawal from benzodiazepines appears to be more severe when high doses or short-acting agents are used. [4]
A 1993 meta-analysis comprehensively evaluated the dependence potential and withdrawal profiles of benzodiazepines categorized by their half-life and potency. Data were systematically aggregated from multiple randomized controlled trials and observational studies involving a total of 1,302 subjects exposed to various benzodiazepines. The analysis stratified benzodiazepines into short- versus long-acting agents as well as high- versus low-potency classifications to assess differential impacts on the development of physical dependence, withdrawal severity, and rebound anxiety phenomena. Results demonstrated a statistically significant higher incidence of withdrawal-related anxiety symptoms and dropout rates among patients treated with short half-life benzodiazepines compared to their long half-life counterparts (p<0.004). High-potency, short half-life agents were particularly associated with more pronounced rebound anxiety and greater challenges during tapering protocols, as evidenced by elevated Hamilton Anxiety Scale scores and increased therapy discontinuations. Although heterogeneity among studies was noted, pooled effect sizes reinforced the notion that short-acting benzodiazepines carry a higher risk of physical dependence and withdrawal syndrome. Conversely, long half-life benzodiazepines showed lower withdrawal symptomatology and better patient retention during discontinuation phases, suggesting a pharmacokinetic advantage in reducing dependence potential. The meta-analysis underscores the clinical imperative to consider benzodiazepine pharmacodynamics when prescribing and managing long-term therapy to mitigate withdrawal morbidity. [5]